The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
After SharkTank’s Mark Cuban teased that his online pharmacy (Mark Cuban Cost Plus Drug Company) would eventually add biosimilars to its list of low-cost drugs in February, Coherus Biosciences announced that it will join forces with Cuban’s company to make an biosimilar referencing Humira (adalimumab) available to patients at an affordable price.
The biosimilar, Yusimry (adalimumab-aqvh), was approved in December 2021 and is projected to launch in July 2023. It is 1 of 9 FDA-approved adalimumab biosimilars and is a low-concentration, citrate-free product. It is a tumor necrosis factor inhibitor indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.
“We believe there is a large, unmet need for improved access and affordability for patients in the U.S. health care system that together Cost Plus Drugs and Yusimry can help address…. This agreement is part of our biosimilar strategy to leverage our excellence in manufacturing and supply chain management to deliver safe and effective biosimilars with ensured, reliable supply,” commented Denny Lanfear, CEO of Coherus.
Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) will offer Yusimry to customers at $569.27 plus dispensing and shipping fees beginning in July 2023. The biosimilar will be available with an autoinjector presentation featuring a 29-gauge needle.
Yusimry will also be included in the Team Cuban Card prescription benefit program through participating pharmacies. The Team Cuban Card allows for patients to obtain their prescriptions from a local independent pharmacy at the same price they would get at Cost Plus Drugs. The program also provides the independent pharmacy community with reasonable dispensing fees and a transparent pricing structure.
“Cost Plus Drugs is saving patients hundreds and thousands of dollars a month by pricing our medications fairly at our cost plus 15%.... Adding Yusimry, a biosimilar of Humira, to Cost Plus Drugs will extend these savings to biologics. This is just our first step in making biologics affordable for patients,” said Cuban.
Cuban is best known as an investor on ABC’s Shark Tank as well as the owner of the Dallas Mavericks. He started his career as an entrepreneur by creating MicroSolutions, a computer consulting service, which he sold in 1990 for $6 million. He announced the launch of his online pharmacy in January 2022.
Cuban spoke at the Association for Accessible Medicines (Access 2023) as part of a fireside chat in February 2023, where he talked about why he chose to develop an online pharmacy that specializes in low-cost medicines and acts as a disruptor to big pharmaceutical wholesale manufacturers. During the talk, he said that while Cost Plus Drugs only carried generic medications at the time, he wasn’t going to rule out adding biosimilar options down the road.
“Humira is the top-selling medicine of all time, but for those without insurance or who are underinsured, this therapy and other biologic medicines have been out of reach due to price,”. said Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company, in a statement from Coherus.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.